Non-small cell lung cancer (NSCLC)

Lung cancer
#Johnson & Johnson #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology #Phase III trial

Amivantamab shown to extend survival in advanced NSCLC

Johnson & Johnson has announced final overall survival (OS) results from the Phase III PAPILLON study of first-line intravenous (IV) Rybrevant (amivantamab).  The fully-human EGFR-MET bispecific antibody was assessed with carboplatin-pemetrexed chemotherapy, versus chemotherapy alone, in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth… Read More

#Cancer Research #News #Trending News

GSK offices
#Biopharma #GSK #Non-small cell lung cancer (NSCLC)

GSK acquires Nuvalent and cancer therapy pipeline 

GSK has reached an agreement to acquire biopharmaceutical company Nuvalent for $10.6 billion.  The agreement includes GSK’s purchase of three therapies for lung cancer, including Zidesamtinib (NVL-250) and neladalkib (NVL-655). The candidates are late-stage, potential best-in-class, next-generation, highly selective ROS1 and ALK inhibitors for treatment of non-small cell lung cancer (NSCLC). … Read More

#Business & Investment #News #Trending News

Non-small cell lung cancer
#Lung cancer #National Institute for Health and Care Excellence (NICE) #NHS #Non-small cell lung cancer (NSCLC) #Regeneron Pharmaceuticals

NICE recommends lung cancer combination therapy 

The National Institute for Health and Care Excellence (NICE) has recommended cemiplimab in combination with platinum-based chemotherapy to treat patients with non-small cell lung cancer (NSCLC).  Cemiplimab is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T cells, which was shown to block cancer cells from using the PD-1… Read More

#News #Regulatory

#Cancer research #Gut microbiome #Immuno-oncology #Melanoma #Non-small cell lung cancer (NSCLC)

Improving response: Microbiome-based approaches to checkpoint inhibitor resistance

Sheri Simmons, Acting Chief Scientific Officer at MaaT Pharma, explores how a diversified gut microbiome could improve the treatment of cancer.   Harnessing the microbiome is emerging as a promising strategy to enhance the body’s response to certain anti-cancer therapies and to mitigate treatment-related toxicities (1). Clinical evidence indicates that gut microbiome composition contributes to patient… Read More

#Cancer Research #Exclusive Content

Non-small cell lung cancer
#Clinical trial #Gut microbiome #Non-small cell lung cancer (NSCLC)

First patient randomised in NSCLC Phase II trial 

The first patient has been randomised in a Phase II trial evaluating an oral microbiome therapy in combination with Cemiplimab to treat patients with advanced non-small cell lung cancer (NSCLC).  Maat033, an oral microbiome developed by biotechnology company MaaT Pharma, is being studied as a treatment in combination with Cemiplimab in enhancing disease… Read More

#News

Cancer cells
#EpiBiologics #Financing #Non-small cell lung cancer (NSCLC) #Oncology

Biotech startup raises $107m to advance oncology candidates 

Biotech startup EpiBiologics has raised $107 million Series B financing to support its pipeline of novel bispecific antibodies.  The financing, co-led by Google Ventures and Johnson & Johnson, will be used to advance candidate EPI-326 into a first-in-human clinical trial for treatment of EGFR-driven lung cancer and head and neck cancer.  EPI-326… Read More

#Business & Investment #News

Non-small cell lung cancer
#BeOne Medicines #CHMP #European Medicines Agency #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology

Positive CHMP opinion for Tevimbra in neoadjuvant/adjuvant NSCLC

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of Tevimbra (tislelizumab) for resectable non-small cell lung cancer (NSCLC).  It is recommended in combination with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment, for adult patients at… Read More

#News #Regulatory

Lung cancer
#Clinical trial #Johnson & Johnson #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology

Rybrevant and Lazcluze extend survival in NSCLC

Results from its first-line MARIPOSA trial show that Rybrevant (amivantamab) plus Lazcluze (lazertinib) significantly extended overall survival (OS) versus osimertinib in the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).  The patients have NSCLC with epidermal growth factor receptor (EGFR)… Read More

#News

FDA
#Boehringer Ingelheim #FDA #Non-small cell lung cancer (NSCLC) #Oncology

Targeted medicine for NSCLC receives FDA Priority Review

The US Food and Drug Administration (FDA) has granted Priority Review to Boehringer Ingelheim’s new drug application for zongertinib for unresectable or metastatic non-small cell lung cancer (NSCLC).  It is indicated for adult patients whose tumours have HER2 (ERBB2) mutations and who have received prior systemic therapy.   Under Priority Review,… Read More

#News #Regulatory

Non-small cell lung cancer
#Bispecific Antibodies #European Commission #Johnson & Johnson #Non-small cell lung cancer (NSCLC) #Oncology

Bispecific antibody combo for NSCLC could extend life by a year

The European Commission (EC) has approved a Marketing Authorisation (MA) for Lazcluze (lazertinib), in combination with Rybrevant (amivantamab).  It is approved for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or exon 21 L858R (L858R)… Read More

#News #Regulatory

Lung cancer
#European Commission #Johnson & Johnson #Lung cancer #Non-small cell lung cancer (NSCLC)

EC approves chemo-free combination for mutated NSCLC 

The European Commission (EC) has extended the approval for Rybrevant (amivantamab), in combination with Lazcluze (lazertinib), to the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC).  It is specifically approved for use in patients with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or exon… Read More

#News #Regulatory

Lungs
#Boehringer Ingelheim #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology #Phase I trial

Over 60% response in lung cancer tumours with rare mutation

Boehringer Ingelheim has reported positive results from its Phase Ib primary analysis of Cohort 1 of the Beamion LUNG-1 trial evaluating zongertinib (BI 1810631) in pre-treated patients with advanced non-small cell lung cancer (NSCLC) with activating HER2 mutations. Zongertinib, an investigational oral HER2 tyrosine kinase inhibitor… Read More

#Cancer Research #News #Trending News

Non-small cell lung cancer
#FDA #Johnson & Johnson #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology

FDA approves combination therapy for non-small lung cancer

The US Food and Drug Administration (FDA) has approved lazertinib (Lazcluze) in combination with amivantamab-vmjw (Rybrevant) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). It is approved in NSCLC with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations,… Read More

#News #Regulatory

Non-small cell lung cancer
#Checkpoint inhibitor therapies #iOnctura #Lung cancer #Non-small cell lung cancer (NSCLC) #Phase II trial

Cancer ‘master switch’ study expands to lung cancer

iOnctura has expanded its clinical trial programme for roginolisib to include non-small cell lung cancer (NSCLC). Via clinical collaboration agreements with the ETOP IBCSG Partners Foundation and GSK, roginolisib will be evaluated in a Phase II study in combination with dostarlimab in patients with NSCLC… Read More

#Cancer Research #News

#Cancer research #Clinical trials #Funding #iOnctura #Non-small cell lung cancer (NSCLC) #Seed funding

iOnctura announces €80m to progress pipeline  

iOnctura has closed an €80 million Series B financing to continue developing a portfolio of precision oral small molecules that target cancers in novel ways.   The funding round was led by new investor Syncona Limited with participation by the EIC Fund, the venture arm of the European Innovation Council… Read More

#Business & Investment #Cancer Research #News

#Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology #University of California

Genetically engineered dendritic cells enhance lung cancer therapy

A study by researchers at the UCLA Health Jonsson Comprehensive Cancer Center in the US suggests that injecting engineered dendritic cells directly into cancerous lung tumours can help promote a stronger immune response. When tested in mice with non-small cell lung cancer (NSCLC), the team discovered… Read More

#Cancer Research #News